Table of Contents:
Earn Continuing Medical Education Credit
A Word From the Editor
Introduction
Background
Targeted Agents in the Adjuvant Setting
Rationale for the Use of Anti-VEGF Antibody in the Adjuvant Setting
Rationale for the Use of Anti-EGFR Antibodies in the Adjuvant Setting
Targeted Agents Successfully Used in Other Adjuvant Settings
To Use or Not To Use Antibodies in the Adjuvant Treatment of Resected Colorectal Cancer
Key Points
References
CONTINUING MEDICAL EDUCATION
Activity Release Date: October 1, 2008
Activity Expiration Date: October 1, 2009
About the Activity
This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC. After completing this series of activities, the clinician should be able to:
(1) Demonstrate knowledge of the phase III studies that have established a role for biologic agents in the metastatic setting, and be able to incorporate a game plan, tailored to the individual, using biologic agents and chemotherapy in this setting
(2) Demonstrate knowledge of adjuvant studies of biologic agents, the biologic agents already approved in the metastatic setting, the possible use of biomarkers, and next generation targets and agents
(3) Apply a solid treatment strategy when dealing with toxicity issues resulting from biologic therapy
(4) Appraise the use of dual targeted therapy (EGFR and VEGF)
Target Audience
This activity targets physicians in the fields of oncology and hematology.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME LLC and The Oncology Group. CME LLC is accredited by the ACCME to provide continuing medical education for physicians.
Continuing Education Credit
AMA PRA Category 1 Credit™ .
CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Compliance Statement
This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
However, CME LLC, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.
Financial Disclosures
Dr. Marshall has acted as a speaker for, received research support from, and acted as a consultant for Roche, Sanofi, Pfizer, Genentech, Bristol-Myers Squibb, and Amgen. Dr. Helft has served on the speakers bureau for Sanofi-Aventis and Genentech; and has acted as a consultant for Sanofi-Aventis.
Copyright
Copyrights owned by CME LLC. Copyright © 2008. All rights reserved.
Contact Information
We would like to hear your comments regarding this or other activities provided by CME LLC. In addition, suggestions for future activities are welcome. Contact us at:
Director of Continuing Education
CME LLC
Harborside Financial Center
Plaza 3, Suite #806
Jersey City, NJ 07311
Phone: 888-618-5781
